MX384236B - Productos farmaceuticos mejorados de peptido para resistencia a la insulina - Google Patents

Productos farmaceuticos mejorados de peptido para resistencia a la insulina

Info

Publication number
MX384236B
MX384236B MX2020000201A MX2020000201A MX384236B MX 384236 B MX384236 B MX 384236B MX 2020000201 A MX2020000201 A MX 2020000201A MX 2020000201 A MX2020000201 A MX 2020000201A MX 384236 B MX384236 B MX 384236B
Authority
MX
Mexico
Prior art keywords
insulin resistance
improved peptide
peptide pharmaceuticals
pharmaceuticals
modified peptides
Prior art date
Application number
MX2020000201A
Other languages
English (en)
Inventor
John J Nestor
Original Assignee
Mederis Diabetes Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mederis Diabetes Llc filed Critical Mederis Diabetes Llc
Publication of MX384236B publication Critical patent/MX384236B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos de síntesis y usos terapéuticos de péptidos y/o proteínas modificados covalentemente. Los péptidos y/o proteínas modificados covalentemente permiten propiedades farmacéuticas mejoradas de productos terapéuticos a base de péptido y/o proteína.
MX2020000201A 2014-05-28 2015-05-28 Productos farmaceuticos mejorados de peptido para resistencia a la insulina MX384236B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462004156P 2014-05-28 2014-05-28
PCT/US2015/033042 WO2015184177A1 (en) 2014-05-28 2015-05-28 Improved peptide pharmaceuticals for insulin resistance

Publications (1)

Publication Number Publication Date
MX384236B true MX384236B (es) 2025-03-14

Family

ID=54699825

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020000201A MX384236B (es) 2014-05-28 2015-05-28 Productos farmaceuticos mejorados de peptido para resistencia a la insulina
MX2016015594A MX371033B (es) 2014-05-28 2015-05-28 Productos farmacéuticos mejorados de péptido para resistencia a la insulina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016015594A MX371033B (es) 2014-05-28 2015-05-28 Productos farmacéuticos mejorados de péptido para resistencia a la insulina.

Country Status (18)

Country Link
US (5) US9856306B2 (es)
EP (2) EP4397374A3 (es)
JP (4) JP6697807B2 (es)
KR (3) KR20230084337A (es)
CN (5) CN106661097A (es)
AU (3) AU2015266854B2 (es)
BR (1) BR112016027595B1 (es)
CA (1) CA2949701C (es)
DK (1) DK3155017T3 (es)
ES (1) ES2985732T3 (es)
FI (1) FI3155017T3 (es)
HU (1) HUE066179T2 (es)
IL (3) IL285613B2 (es)
MX (2) MX384236B (es)
NZ (2) NZ726623A (es)
PL (1) PL3155017T3 (es)
PT (1) PT3155017T (es)
WO (1) WO2015184177A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012158962A2 (en) 2011-05-18 2012-11-22 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
KR20240110072A (ko) 2011-05-18 2024-07-12 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
WO2014081864A1 (en) * 2012-11-20 2014-05-30 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
JP6525456B2 (ja) * 2012-11-20 2019-06-05 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチド製剤
US9856306B2 (en) 2014-05-28 2018-01-02 Spitfire Pharma, Inc. Peptide pharmaceuticals for insulin resistance
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
WO2019018350A1 (en) 2017-07-17 2019-01-24 Keith Roizman TOPICAL ADMINISTRATION OF THERAPEUTIC AGENTS COMPRISING CELL PENETRATION PEPTIDES, FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER OCULAR DISEASES
EP3735295B1 (en) 2018-01-03 2024-08-21 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders
KR20220143923A (ko) * 2020-02-21 2022-10-25 스핏파이어 파마, 엘엘씨 Glp-1r 및 gcgr 효능제, 제형 및 사용 방법
WO2022125598A1 (en) * 2020-12-07 2022-06-16 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists
US12171806B2 (en) 2021-09-28 2024-12-24 Spitfire Pharma Llc Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists
CN113461747B (zh) * 2021-07-12 2023-02-03 吉林化工学院 刺玫果中2个具有降血糖活性的化合物
WO2024239961A1 (zh) * 2023-05-24 2024-11-28 联邦生物科技(珠海横琴)有限公司 一种胰岛素衍生物及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3219656A (en) 1963-08-12 1965-11-23 Rohm & Haas Alkylpolyalkoxyalkyl glucosides and process of preparation therefor
US3839318A (en) 1970-09-27 1974-10-01 Rohm & Haas Process for preparation of alkyl glucosides and alkyl oligosaccharides
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DK149776C (da) 1984-01-06 1987-04-21 Orion Yhtymae Oy Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen
AT382381B (de) 1984-10-02 1987-02-25 Oesterr Zuckerfab Evidenz Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
JPH1160598A (ja) 1997-08-15 1999-03-02 Asahi Glass Co Ltd オピオイド様ペプチド
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
RU2181729C1 (ru) 2000-09-20 2002-04-27 Калюжин Олег Витальевич Производные мурамовой кислоты
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6864069B2 (en) * 2001-10-05 2005-03-08 Bayer Pharmaceuticals Corporation Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
US20110257096A1 (en) 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
ITRM20040607A1 (it) 2004-12-15 2005-03-15 Biogen S R L Analoghi della dermorfina ad attivita' analgesica.
US7776819B2 (en) 2005-03-03 2010-08-17 The Board Of Trustees Of The University Of Illinois Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization
EP1883419A4 (en) * 2005-05-06 2010-08-04 Bayer Pharmaceuticals Corp GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES
WO2007002465A2 (en) 2005-06-23 2007-01-04 Rapid Pharmaceuticals, Llc Stabilizing alkylglycoside compositions and methods thereof
EP2045265B1 (en) 2005-09-22 2012-11-21 Biocompatibles Uk Ltd. GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance
WO2007060692A2 (en) 2005-11-24 2007-05-31 Brain N' Beyond Biotech Pvt. Ltd. Compositions for increasing bioavailability of peptides or proteins and method thereof
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008052043A2 (en) 2006-10-24 2008-05-02 Cogenesys, Inc. Opioid receptor agonist fusion proteins
EP1961765A1 (en) 2006-12-08 2008-08-27 Zealand Pharma A/S Truncated PTH peptides with a cyclic conformation
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
CA2728284C (en) 2008-06-17 2019-09-10 Richard D. Dimarchi Glucagon/glp-1 receptor co-agonists
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
WO2012088116A2 (en) 2010-12-22 2012-06-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR101453037B1 (ko) 2011-03-23 2014-10-21 주식회사 엘지화학 전극조립체 및 이의 제조방법
KR20240110072A (ko) * 2011-05-18 2024-07-12 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
WO2012158962A2 (en) * 2011-05-18 2012-11-22 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
JP6525456B2 (ja) 2012-11-20 2019-06-05 メデリス ダイアビーティーズ，エルエルシー インスリン抵抗性のための改善されたペプチド製剤
WO2014081864A1 (en) 2012-11-20 2014-05-30 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
WO2014170496A1 (en) * 2013-04-18 2014-10-23 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US9856306B2 (en) 2014-05-28 2018-01-02 Spitfire Pharma, Inc. Peptide pharmaceuticals for insulin resistance
CA3093383A1 (en) * 2014-10-24 2016-04-28 Merck Sharp & Dohme Corp. Co-agonists of the glucagon and glp-1 receptors
EP3735295B1 (en) * 2018-01-03 2024-08-21 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders

Also Published As

Publication number Publication date
AU2015266854B2 (en) 2020-03-26
CA2949701C (en) 2023-12-12
WO2015184177A1 (en) 2015-12-03
US20250136656A1 (en) 2025-05-01
ES2985732T3 (es) 2024-11-07
HUE066179T2 (hu) 2024-07-28
AU2023200659A1 (en) 2023-05-11
US20200277351A1 (en) 2020-09-03
US9856306B2 (en) 2018-01-02
AU2020203609A1 (en) 2020-06-25
US20250313604A1 (en) 2025-10-09
KR20250007694A (ko) 2025-01-14
KR102542164B1 (ko) 2023-06-12
JP2020143066A (ja) 2020-09-10
EP4397374A2 (en) 2024-07-10
EP4397374A3 (en) 2024-10-16
FI3155017T3 (fi) 2024-04-17
DK3155017T3 (da) 2024-04-15
CA2949701A1 (en) 2015-12-03
EP3155017B1 (en) 2024-01-10
US20170096468A1 (en) 2017-04-06
BR112016027595A2 (pt) 2017-08-15
AU2015266854A1 (en) 2016-12-15
US20180194826A1 (en) 2018-07-12
US10577405B2 (en) 2020-03-03
AU2020203609B2 (en) 2022-11-17
EP3155017A1 (en) 2017-04-19
IL249044B (en) 2020-07-30
PT3155017T (pt) 2024-05-14
IL275526A (en) 2020-08-31
EP3155017A4 (en) 2019-03-27
BR112016027595A8 (pt) 2021-07-20
IL285613A (en) 2021-09-30
JP6697807B2 (ja) 2020-05-27
MX371033B (es) 2020-01-13
BR112016027595B1 (pt) 2023-12-26
KR20230084337A (ko) 2023-06-12
CN109865142A (zh) 2019-06-11
KR20170010412A (ko) 2017-01-31
NZ726623A (en) 2020-02-28
JP2017519739A (ja) 2017-07-20
CN117582516A (zh) 2024-02-23
IL275526B (en) 2021-08-31
NZ757113A (en) 2022-08-26
CN106661097A (zh) 2017-05-10
MX2016015594A (es) 2017-03-23
AU2015266854A2 (en) 2017-03-09
JP2022172128A (ja) 2022-11-15
IL249044A0 (en) 2017-01-31
NZ764813A (en) 2024-07-05
PL3155017T4 (pl) 2024-06-17
PL3155017T3 (pl) 2024-06-17
CN117180445A (zh) 2023-12-08
IL285613B1 (en) 2024-07-01
CN113264994A (zh) 2021-08-17
JP2024102119A (ja) 2024-07-30
IL285613B2 (en) 2024-11-01

Similar Documents

Publication Publication Date Title
MX2018013981A (es) Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina.
MX384236B (es) Productos farmaceuticos mejorados de peptido para resistencia a la insulina
MX344219B (es) Productos farmaceuticos peptidicos mejorados para resistencia a insulina.
WO2012158964A3 (en) Improved peptide pharmaceuticals for osteoporosis
CY1122803T1 (el) Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων
IL251462A0 (en) Pharmaceutical formulations for oral administration of peptide or protein drugs
BR112018072783A2 (pt) proteínas de fusão elp para liberação controlada e retardada
EP3200812A4 (en) Novel 4 7 peptide monomer and dimer antagonists
EP3281627A4 (en) Soluble microneedle for delivering proteins or peptides
EP3265472A4 (en) Cytotoxic hexim1 peptides and uses thereof
ZA201903657B (en) Ras protein degradation inducing molecule and pharmaceutical composition
IL252902A0 (en) Amino acid and peptide conjugates and their uses
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
EP3186272A4 (en) Functionalized beta-sheet peptide stabilized membrane proteins, constructs comprising same, and methods of forming and using same
ZA201904386B (en) S-arrestin peptides and therapeutic uses thereof
NZ746677A (en) Novel alpha-1-microglobulin derived proteins and their use
EP3256578B8 (en) Polypeptides for engineering integrase chimeric proteins and their use in gene therapy
EP3345003A4 (en) IDENTIFICATION OF PROTEINS IN THE ABSENCE OF PEPTIDE IDENTIFICATION
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
HK40007738A (en) Particles for delivery of proteins and peptides
EP3269731A4 (en) Molecular design of recombinant protein drug
HK40016468A (en) S-arrestin peptides and therapeutic uses thereof
HK40017229A (en) Constructs targeting histone h3 peptide/mhc complexes and uses thereof
HK1241861A1 (en) Amino acid and peptide conjugates and uses thereof
HK1235280A1 (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs